将多效药片投入实践:挑战与经验教训
多效药片的心血管适应证监管批准在30多个国家迅速增加,证据清楚显示其可改善依从性和心血管病危险因素。但广泛实施面临政府报销缺失和医生采纳不佳等挑战,需WHO等全球机构及政府教育、倡导、认可和实施才能获得完整公共卫生获益。
要点
- 多效药片在30多个国家获监管批准,证据显示可改善依从性和心血管病危险因素。
- 临床试验文献提示多效药片策略具有成本效益、使用安全性、依从性大幅改善和危险因素控制优于常规照护。
- 广泛实施受政府报销缺失和医生采纳不佳阻碍,需WHO等全球机构及政府推动。
核心结论
- 多效药片可改善有适应证患者(已确诊心血管病或高危者)的依从性和心血管病危险因素,但广泛实施面临挑战,需WHO等全球机构及政府教育、倡导、认可和实施才能获得完整公共卫生获益。
研究设计与样本
- 本文为综述,总结多效药片临床试验文献及各国商业推广后的实地经验,未报告系统检索范围。
主要发现
- 多效药片的心血管适应证监管批准在30多个国家迅速增加。
- 临床试验文献提示多效药片策略具有成本效益、使用安全性、依从性大幅改善和危险因素控制优于常规照护。
- 政府报销缺失和医生采纳不佳(来自各国商业推广后的实地经验)严重阻碍了真实世界实施。
关键数值与推荐
- 多效药片适用于有使用其组分适应证的患者,即已确诊心血管病或高危者。
临床怎么用
- 作者认为获得多效药片的完整公共卫生获益需要WHO和国家临床机构等关键全球机构以及政府进行教育、倡导、认可和实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regulatory approvals for cardiovascular polypills are increasing rapidly across more than 30 countries. The evidence clearly shows polypills improve adherence and cardiovascular disease risk factors for patients with indications for use of polypill components-ie, those with established cardiovascular disease or at high risk. However, the implementation of polypills into clinical practice has many challenges. The clinical trials literature provides insights into the clinical impact of a polypill strategy, including cost-effectiveness, safety of use, substantial improvement in adherence, and better risk factor control than usual care. Despite the clear need for such a strategy and the available clinical data backing up the use of the polypill in different patient populations, challenges to widespread implementation, such as an absence of government reimbursement and poor physician uptake (identified from on the ground experience in countries following commercial rollout), have greatly obstructed real-world implementation. Obtaining the full public health benefit of polypills will require education, advocacy, endorsement, and implementation by key global agencies such as WHO and national clinical bodies, as well as endorsement from governments.
引用
- Webster R, Castellano JM, Onuma OK, et al. Putting polypills into practice: challenges and lessons learned. Lancet. 2017. PMID: 28290996. doi:10.1016/S0140-6736(17)30558-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。